Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
Open Access
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 152 (3) , 560-567
Abstract
No abstract availableKeywords
Funding Information
- TESARO, Inc
This publication has 11 references indexed in Scilit:
- Niraparib in Recurrent Ovarian CancerNew England Journal of Medicine, 2017
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerNew England Journal of Medicine, 2016
- Improving outcomes for older women with gynaecological malignanciesCancer Treatment Reviews, 2016
- Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: Results of a pooled analysis of three GINECO phase II trialsGynecologic Oncology, 2016
- The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 YearsFrontiers in Oncology, 2016
- Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experienceCancer, 2010
- Declining p53 function in the aging process: A possible mechanism for the increased tumor incidence in older populationsProceedings of the National Academy of Sciences, 2007
- Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged ≥70 years with advanced ovarian cancer—a study by the AGO OVAR GermanyAnnals of Oncology, 2007
- Treatment patterns by decade of life in elderly women (≥70 years of age) with ovarian cancerGynecologic Oncology, 2005
- Management of Cancer in the Older Person: A Practical ApproachThe Oncologist, 2000